Payment overview · 2025
General Payments
$955.29
37 reported records · 16 companies
Healthcare provider profile · identity verified
David P Rawdon, MD
Allopathic & Osteopathic Physicians|Family Medicine · BELLEVILLE, IL · NPI 1376549139
Verified facts
What the public records show
CMS Open Payments records show David P Rawdon, MD received $955.29 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $246.62 | 25.8% | 7 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $114.37 | 12.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.78 | 10.7% | 5 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.32 | 8.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.71 | 6.6% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $49.37 | 5.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.05 | 4.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.66 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.78 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.07 | 3.6% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.54 | 3.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.40 | 2.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.89 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.12 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.07 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.75 | 36 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.84 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.38 | 4 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $114.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.76 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $85.32 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $65.07 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.81 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.81 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 314 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 174 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 235 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 231 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
27 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
314 | 78 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
235 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
231 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1223 | 402 |
| Amlodipine Besylate | Amlodipine Besylate | 965 | 319 |
| Levothyroxine Sodium | Levothyroxine Sodium | 919 | 275 |
| Lisinopril | Lisinopril | 755 | 242 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 751 | 251 |
| Omeprazole | Omeprazole | 647 | 210 |
| Losartan Potassium | Losartan Potassium | 625 | 200 |
| Metoprolol Succinate | Metoprolol Succinate | 530 | 174 |
| Gabapentin | Gabapentin | 522 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 160 |
| Hydrochlorothiazide | Hydrochlorothiazide | 470 | 146 |
| Simvastatin | Simvastatin | 422 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 415 | 125 |
| Metformin Hcl | Metformin Hcl | 402 | 133 |
| Furosemide | Furosemide | 384 | 136 |
| Trazodone Hcl | Trazodone Hcl | 346 | 109 |
| Metformin Hcl Er | Metformin Hcl | 332 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 321 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 113 |
| Farxiga | Dapagliflozin Propanediol | 314 | 78 |
| Potassium Chloride | Potassium Chloride | 299 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 89 |
| Montelukast Sodium | Montelukast Sodium | 249 | 97 |
| Duloxetine Hcl | Duloxetine Hcl | 245 | 68 |
| Meloxicam | Meloxicam | 241 | 76 |
| Mounjaro | Tirzepatide | 235 | 54 |
| Sertraline Hcl | Sertraline Hcl | 235 | 70 |
| Ozempic | Semaglutide | 231 | 52 |
| Ezetimibe | Ezetimibe | 224 | 74 |
| Allopurinol | Allopurinol | 214 | 68 |
| Famotidine | Famotidine | 192 | 65 |
| Eliquis | Apixaban | 187 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 67 |
| Carvedilol | Carvedilol | 176 | 57 |
| Jardiance | Empagliflozin | 174 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 172 | 52 |
| Glimepiride | Glimepiride | 171 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 41 |
| Alendronate Sodium | Alendronate Sodium | 167 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 80 |
| Citalopram Hbr | Citalopram Hydrobromide | 154 | 42 |
| Alprazolam | Alprazolam | 147 | 55 |
| Tramadol Hcl | Tramadol Hcl | 133 | 54 |
| Celecoxib | Celecoxib | 131 | 36 |
| Buspirone Hcl | Buspirone Hcl | 129 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 50 |
| Xarelto | Rivaroxaban | 125 | 33 |
| Atenolol | Atenolol | 122 | 32 |
| Prednisone | Prednisone | 121 | 77 |
| Fluoxetine Hcl | Fluoxetine Hcl | 120 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 114 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 34 |
| Finasteride | Finasteride | 111 | 36 |
| Spironolactone | Spironolactone | 106 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 104 | 28 |
| Bupropion Xl | Bupropion Hcl | 101 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 19 |
| Memantine Hcl | Memantine Hcl | 95 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 34 |
| Trulicity | Dulaglutide | 94 | 18 |
| Synthroid | Levothyroxine Sodium | 91 | 21 |
| Valsartan | Valsartan | 91 | 28 |
| Methylprednisolone | Methylprednisolone | 85 | 80 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 81 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 26 |
| Myrbetriq | Mirabegron | 72 | 17 |
| Naproxen | Naproxen | 72 | 26 |
| Donepezil Hcl | Donepezil Hcl | 70 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 15 |
| Meclizine Hcl | Meclizine Hcl | 65 | 23 |
| Valacyclovir | Valacyclovir Hcl | 62 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 24 |
| Ondansetron Odt | Ondansetron | 59 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 19 |
| Mirtazapine | Mirtazapine | 56 | 13 |
| Ramipril | Ramipril | 56 | 18 |
| Lovastatin | Lovastatin | 55 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 22 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 50 |
| Lorazepam | Lorazepam | 54 | 13 |
| Ibuprofen | Ibuprofen | 53 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 44 |
| Indapamide | Indapamide | 52 | 15 |
| Irbesartan | Irbesartan | 50 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 21 |
| Klor-Con M20 | Potassium Chloride | 48 | 19 |
| Clonidine Hcl | Clonidine Hcl | 46 | 18 |
| Clonazepam | Clonazepam | 45 | 11 |
| Telmisartan | Telmisartan | 44 | 14 |
| Chlorthalidone | Chlorthalidone | 43 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 14 |
| Lansoprazole | Lansoprazole | 43 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 43 | 21 |
| Pregabalin | Pregabalin | 42 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 16 |
| Insulin Aspart Flexpen | Insulin Aspart | 40 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 18 |
| Primidone | Primidone | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | 13 |
| Amoxicillin | Amoxicillin | 38 | 34 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 11 |
| Topiramate | Topiramate | 38 | 16 |
| Acyclovir | Acyclovir | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | 11 |
| Lidocaine | Lidocaine | 36 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 13 |
| Azelastine Hcl | Azelastine Hcl | 34 | 16 |
| Fenofibrate | Fenofibrate | 34 | 13 |
| Nystatin | Nystatin | 34 | 21 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 29 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Risperidone | Risperidone | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 13 |
| Prolia | Denosumab | 27 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 12 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 11 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 15 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Tadalafil | Tadalafil | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 12 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Embrace Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $955.29 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, AREXVY, AUSTEDO XR, AYVAKIT, BREZTRI, CREON, Cologuard Collection Kit, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Tlando, VIBERZI, VYNDAMAX, Veozah, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error